Drugs in MeSH Category Antineoplastic Agents, Phytogenic

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gland	PACLITAXEL	paclitaxel	INJECTABLE;INJECTION	207326-001	Aug 23, 2016	AP	RX	No	No
Bristol Myers Squibb	VINCREX	vincristine sulfate	INJECTABLE;INJECTION	070867-001	Jul 12, 1988		DISCN	No	No
Actavis Totowa	PACLITAXEL	paclitaxel	INJECTABLE;INJECTION	090130-001	Dec 9, 2009	AP	RX	No	No
Onesource Specialty	VEPESID	etoposide	CAPSULE;ORAL	019557-002	Dec 30, 1986		DISCN	Yes	No
Bristol-myers	ABRAXANE	paclitaxel	POWDER;INTRAVENOUS	021660-001	Jan 7, 2005	AB	RX	Yes	Yes	9,511,046*PED				Y
Hospira	VINCRISTINE SULFATE	vincristine sulfate	INJECTABLE;INJECTION	071559-001	Apr 11, 1988		DISCN	No	No
Abic	VINCRISTINE SULFATE	vincristine sulfate	INJECTABLE;INJECTION	070873-001	Feb 19, 1987		DISCN	No	No

Market Dynamics and Patent Landscape for Phytogenic Antineoplastic Agents (MeSH: “Antineoplastic Agents”)

Last updated: April 23, 2026

What defines the MeSH scope for “antineoplastic agents, phytogenic”?

MeSH “Antineoplastic Agents” covers therapeutic substances used in the treatment of cancer. The specific phytogenic subset is typically expressed in practice as plant-derived small molecules, extracts, or phytochemical-derived drug candidates positioned for oncology indications (prevention, treatment, or supportive cancer care). MeSH itself is a controlled vocabulary that indexes terms, formulations, and pharmacologic classes; it does not create legal “patent families,” but it is a practical taxonomy for mapping oncology drug innovation that is plant-origin or phytochemical-derived (and for filtering patent and product landscape work).

Market-facing interpretation used for this landscape

• Phytogenic oncology: plant- or phytochemical-derived compounds (including semi-synthetic derivatives where the starting material is phytogenic).
• Drug types: small molecules, natural product derivatives, standardized extracts, or extract-derived actives used in anticancer regimens.
• MeSH mapping: candidates are indexed under oncology pharmacology and then tagged by phytogenic origin in internal/product datasets or in oncology taxonomy layers aligned to MeSH.

How does the phytogenic antineoplastic market behave versus conventional oncology drugs?

The phytogenic segment in oncology is shaped by four dynamics: trial design constraints, regulatory path dependence, IP strategy patterns, and commercialization routes that often differ from large-molecule oncology.

1) Demand drivers

• Unmet need in refractory disease: phytogenic candidates cluster in late-line settings, combination regimens, and symptom control claims when monotherapy benefit is incremental.
• Combination positioning: a common commercialization route is add-on use with chemotherapy, radiotherapy, or targeted therapy, because synergy can reduce required dose exposure and expand use across molecular subtypes.

2) Supply and manufacturing economics

• Batch variability: extract standardization is the operational bottleneck for consistent efficacy and for sustaining clinical and regulatory comparability.
• Input sourcing: plant supply can be volatile, driving cost and schedule risk, and influencing patent filings around purification methods, marker compounds, and standardization specifications.

3) Regulatory and clinical development shape

• Route-to-market divergence:
  • “Purified active” pathways lean toward small-molecule style development.
  • “Standardized extract” pathways require consistency frameworks and analytical method validation that become the IP backbone.
• Safety-dominant early development: many programs start with tolerability packages and dose-finding designs that can be faster than first-in-class targeted oncology biology, but they still face efficacy hurdles for label claims.

4) IP and exclusivity economics

Phytogenic oncology programs often pursue:

• Composition of matter for purified actives or derivatives
• Process patents for extraction, purification, and crystallization
• Use patents for specific indications, patient subsets, dosing regimens, or combination protocols
• Marker-based standardization patents to control product definition

This means the competitive landscape is frequently determined as much by manufacturing definition and dosing claims as by the “plant compound” itself.

Where does the patent value concentrate in phytogenic oncology?

Phytogenic oncology patents typically concentrate in three claim buckets that correspond to how products are actually made and used.

1) Purified active and derivative space

• Purification and enrichment: claims cover specific isolation procedures, chromatographic conditions, and purity thresholds.
• Semi-synthetic derivatives: chemical modifications to improve potency, solubility, stability, or bioavailability create clearer composition-of-matter separation.
• Formulation: salts, amorphous forms, co-crystals, nanoparticles, and lipid-based delivery are common.

2) Standardized extract definition

• Marker compounds: patents define extract composition by quantitative marker ranges rather than by botanicals alone.
• Standardization methods: analytical assays, reference standards, and acceptance criteria are often patented.
• Stability and shelf-life: packaging, formulation stability, and preservation methods.

3) Therapeutic use and regimen claims

• Combination therapy: “phytogenic agent + chemotherapy/targeted therapy” claims are frequent.
• Dosing regimens: specific schedules (daily vs intermittent), sequence of administration, and dose thresholds.
• Specific cancers or biomarkers: claims may target tumor types, stage, or biomarker-defined cohorts.

What is the current patent landscape pattern by innovation type?

Across phytogenic oncology, the landscape generally splits into three layers:

1. Legacy natural product IP
   Many natural products have long histories. The “plant molecule” itself may not be patentable, but downstream improvements are patentable.

2. Contemporary product-definition IP
   Standardization, marker control, extraction and purification, and formulation dominate because these aspects distinguish one product from another even when the actives overlap.

3. Claim-risk concentration in second-generation filings
   If the base compound is known, the highest value tends to sit in:

   • new derivative chemistry
   • new standardized extract specifications
   • new combination regimens with defined endpoints

How does the competitive map look for phytogenic oncology assets?

The competitive map is not cleanly segmented by MeSH alone, because MeSH indexes pharmacologic class, while patents follow product definition and therapeutic use. In practice, the competitive map is best interpreted as an adjacency graph:

• Botanical origin is a starting point
• Purification and formulation define the product
• Clinical indication and combination define commercialization

That produces a landscape where:

• multiple companies may claim different “forms” of the same or similar phytochemicals
• multiple companies may share a plant source but differ on markers, purity, and dosing
• exclusivity often hinges on the narrowest definition: assay thresholds, extraction parameters, and regimen specifics

Which regulatory and exclusivity realities shape patent strategy?

Phytogenic oncology programs typically rely on time-limited exclusivities that create pressure to secure:

• early “priority” on product definition (actives, derivative, extract markers, formulations)
• follow-on patents that survive obviousness/novelty scrutiny through tight specificity

Because clinical benefits often accrue in combination regimens, follow-on use patents frequently outlast pure chemistry filings.

What does MeSH add to the market-patent workflow?

MeSH is a practical filter that:

• groups oncology pharmacology under consistent terminology
• supports systematic discovery across therapeutic categories
• enables linking clinical literature and product dossiers to patent search strategies

For a patent landscape workstream, MeSH helps reduce noise when mapping plant-origin oncology claims to actual therapeutic context and then narrowing to the patent classes most likely to align with those contexts (composition, process, formulation, and use).

How should a patent analyst segment “phytogenic antineoplastic” claims for deal and R&D decisions?

Use a four-part segmentation to avoid overcounting “same plant, different IP”:

Claim segmentation framework

1. Substance layer

   • purified active
   • derivative
   • standardized extract (marker-defined)
   • formulation variant

2. Manufacturing layer

   • extraction and purification method
   • crystallization/precipitation steps
   • analytical standardization and QC acceptance

3. Therapy layer

   • monotherapy indication
   • combination regimens
   • dosing schedule claims

4. Regulatory-defined product layer

   • what constitutes the “drug” in the regulatory dossier
   • equivalence standards and changes post-approval

This segmentation improves risk scoring because it maps patent enforceability to how the product is actually sold and manufactured.

Key Takeaways

• MeSH “Antineoplastic Agents” provides oncology taxonomy; phytogenic subsets require product-definition segmentation because patent value usually concentrates in derivatives, standardized extracts, formulations, manufacturing methods, and combination regimens.
• The phytogenic oncology market behaves like an “IP definition” market as much as a “molecule” market: extract standardization and assay-defined composition create enforceable differentiation.
• Patent strategy typically follows a layered pattern: product definition first (substance, markers, process), then therapeutic use (indication and regimen), then formulation for differentiation and follow-on coverage.
• For analysis and investment screening, avoid counting botanicals as the same asset across competitors; segment by substance, manufacturing, therapy claims, and regulatory-defined product scope.

FAQs

1. Why does phytogenic oncology patent value concentrate in extract markers and processes?
   Because plants and many phytochemicals are known; enforceable separation often requires specifying measurable composition ranges and manufacturing parameters that define the marketed product.

2. What claim types most often block generic or competitor entry in phytogenic antineoplastic products?
   Composition definitions tied to purified actives or marker-defined extracts, plus use claims for specific combinations and dosing regimens.

3. How does MeSH help patent landscape work when “phytogenic” is not purely a patent category?
   MeSH standardizes oncology context so search logic can map clinical indication patterns to likely patent claim categories (use, formulation, composition, process).

4. Is combination-therapy IP more common than monotherapy IP in phytogenic antineoplastic development?
   Yes, because combination use can support differentiation and label-relevant efficacy when monotherapy effect sizes are harder to establish.

5. What is the highest-risk failure mode in phytogenic antineoplastic patent analysis?
   Overstating asset similarity by botanical source alone without comparing marker ranges, purification specs, derivative identity, and regimen claim scope.

---

References

[1] National Library of Medicine (NLM). MeSH (Medical Subject Headings). https://www.ncbi.nlm.nih.gov/mesh/